Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018

BACKGROUND: In March 2017, Burkina Faso introduced meningococcal serogroup A conjugate vaccine (MACV) into the Expanded Programme on Immunization. MACV is administered to children aged 15–18 months, concomitantly with the second dose of measles-containing vaccine (MCV2). One year after MACV introduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Aksnes, Brooke Noel, Walldorf, Jenny A., Nkwenkeu, Sylvain F., Zoma, Robert L., Mirza, Imran, Tarbangdo, Felix, Fall, Soukeynatou, Hien, Sansan, Ky, Cesaire, Kambou, Ludovic, Diallo, Alpha Oumar, Aké, Flavien H., Hatcher, Cynthia, Patel, Jaymin C., Novak, Ryan T., Hyde, Terri B., Medah, Isaïe, Soeters, Heidi M., Jalloh, Mohamed F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519392/
https://www.ncbi.nlm.nih.gov/pubmed/34579975
http://dx.doi.org/10.1016/j.vaccine.2021.09.038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519392/
https://www.ncbi.nlm.nih.gov/pubmed/34579975
http://dx.doi.org/10.1016/j.vaccine.2021.09.038

Ejemplares similares